A pioneer experience in Malaysia on In-house Radio-labelling of (131)I-rituximab in the treatment of Non-Hodgkin's Lymphoma and a case report of high dose (131)I-rituximab-BEAM conditioning autologous transplant
Copyright © 2016 Elsevier Ltd. All rights reserved..
Radioimmunotherapy is an established treatment modality in Non-Hodgkin's lymphoma. The only two commercially available radioimmunotherapies - (90)Y-ibritumomab tiuxetan is expensive and (131)I-tositumomab has been discontinued from commercial production. In resource limited environment, self-labelling (131)I-rituximab might be the only viable practical option. We reported our pioneer experience in Malaysia on self-labelling (131)I-rituximab, substituting autologous haematopoietic stem cell transplantation (HSCT) and a patient, the first reported case, received high dose (131)I-rituximab (6000MBq/163mCi) combined with BEAM conditioning for autologous HSCT.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:116 |
|---|---|
| Enthalten in: |
Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine - 116(2016) vom: 21. Okt., Seite 13-21 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kuan, Jew Win [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 07.02.2018 Date Revised 10.12.2019 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.apradiso.2016.07.016 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM262945045 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM262945045 | ||
| 003 | DE-627 | ||
| 005 | 20231224202810.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.apradiso.2016.07.016 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0876.xml |
| 035 | |a (DE-627)NLM262945045 | ||
| 035 | |a (NLM)27472826 | ||
| 035 | |a (PII)S0969-8043(16)30390-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kuan, Jew Win |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A pioneer experience in Malaysia on In-house Radio-labelling of (131)I-rituximab in the treatment of Non-Hodgkin's Lymphoma and a case report of high dose (131)I-rituximab-BEAM conditioning autologous transplant |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.02.2018 | ||
| 500 | |a Date Revised 10.12.2019 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2016 Elsevier Ltd. All rights reserved. | ||
| 520 | |a Radioimmunotherapy is an established treatment modality in Non-Hodgkin's lymphoma. The only two commercially available radioimmunotherapies - (90)Y-ibritumomab tiuxetan is expensive and (131)I-tositumomab has been discontinued from commercial production. In resource limited environment, self-labelling (131)I-rituximab might be the only viable practical option. We reported our pioneer experience in Malaysia on self-labelling (131)I-rituximab, substituting autologous haematopoietic stem cell transplantation (HSCT) and a patient, the first reported case, received high dose (131)I-rituximab (6000MBq/163mCi) combined with BEAM conditioning for autologous HSCT | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a (131)I-rituximab | |
| 650 | 4 | |a Iodine-131 | |
| 650 | 4 | |a Non-Hodgkin's lymphoma | |
| 650 | 4 | |a Radioimmunotherapy | |
| 650 | 4 | |a Rituximab | |
| 650 | 7 | |a Antibodies, Monoclonal, Murine-Derived |2 NLM | |
| 650 | 7 | |a Radiopharmaceuticals |2 NLM | |
| 650 | 7 | |a Rituximab |2 NLM | |
| 650 | 7 | |a 4F4X42SYQ6 |2 NLM | |
| 650 | 7 | |a 131I-rituximab |2 NLM | |
| 650 | 7 | |a K2I4B6I9L1 |2 NLM | |
| 700 | 1 | |a Law, Chiong Soon |e verfasserin |4 aut | |
| 700 | 1 | |a Wong, Xiang Qi |e verfasserin |4 aut | |
| 700 | 1 | |a Ko, Ching Tiong |e verfasserin |4 aut | |
| 700 | 1 | |a Awang, Zool Hilmi |e verfasserin |4 aut | |
| 700 | 1 | |a Chew, Lee Ping |e verfasserin |4 aut | |
| 700 | 1 | |a Chang, Kian Meng |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine |d 1994 |g 116(2016) vom: 21. Okt., Seite 13-21 |w (DE-627)NLM074730231 |x 1872-9800 |7 nnns |
| 773 | 1 | 8 | |g volume:116 |g year:2016 |g day:21 |g month:10 |g pages:13-21 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.apradiso.2016.07.016 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 116 |j 2016 |b 21 |c 10 |h 13-21 | ||